Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer

International Journal of Clinical Oncology

Volumn 6, Issue 5, 2001, Pages 242-247

  Ito, Y ^a   Aiba, K ^a   Horikoshi, N ^a   Saotome, T ^a   Irie, T ^a   Sugiyama, K ^a   Nakane, M ^a   Hashimoto, D ^a   Yoshida, N ^a   Mizunuma, N ^a   Takahashi, S ^a   Tanigawara, Y ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Combination; Docetaxel; Doxorubicin; Neutropenia; Weekly

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BOLUS INJECTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0035197771     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012112     Document Type: Article

References (26)

1. Metastatic breast cancer: The role of chemotherapy
2. The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group
3. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
4. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over
5. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
6. Phase III trial of adriamycin (A) vs paclitaxel (T) vs adriamycin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: An intergroup trial
7. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy
8. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
9. Conventional dose CAF therapy versus low dose adriamycin therapy in the treatment of advanced breast cancer
10. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
11. Docetaxel administered on a weekly basis for metastatic breast cancer
12. Paclitaxel and cardiotoxicity
13. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide (FAC) as a first-line therapy for women with metastatic breast cancer. Final results of a randomized phase III multicenter trial
14. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer
15. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
16. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
17. 1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
18. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31510 women
19. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
20. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-22
21. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of adriamycin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
22. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer
23. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment
24. Dose-dense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer
25. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer